In the last year, two significant Federal Court decisions, reported here and here have exposed key flaws in the...
Home / News / Pearce IP Blog
ALL BLOGS BY
Naomi Pearce
Pearce IP BioBlast®: w/e 29 October 2021
22 Oct 21 | Biocon released its Q2 2022 financial results, reporting a 10% increase in biosimilars revenue year on...
Pearce IP BioBlast®: w/e 22 October 2021
14 Oct 21 | Gan & Lee Pharmaceuticals announced the completion of two Ph III studies of its proposed insulin...
Strategies for generic/biosimilar market entry in Australia
Originally published in World Intellectual Property Review 3 2021 After surviving the Great Patent Cliff of 2011–2016,...
Is best practice for patent validity in Australia an impossible task?
The evolution of jurisprudence in Australia can have far reaching implications for legal practitioners in every...
Pearce IP BioBlast®: w/e 15 October 2021
05 Oct 21 | EU | Celltrion announced that it has submitted a Marketing Authorisation Application to the EMA seeking...
Which product infringes? Kangatech ordered to file evidence consistent with pleadings despite later workaround
Date: 20 May 2021 / 18 October 2021Court: Federal Court of AustraliaJudge: Greenwood J Background Australian Patent...
Pearce IP BioBlast®: w/e 08 October 2021
27 Sep 21 | CA | Apobiologix announced that Health Canada has approved Bambevi® (biosimilar bevacizumab) in...
Merck and Pfizer pneumococcal conjugate vaccine settlement prolongs uncertainty regarding Australian product claims
Recently, Merck Sharp & Dohme (MSD) (known as Merck & Co., Inc. in the US and Canada) announced a settlement...
Pearce IP BioBlast®: w/e 01 October 2021
27 Sep 21 | Hikma Pharmaceuticals announced that it will acquire Custopharm for an initial cash consideration of USD...
Taking a position on patent infringement – position statements where multiple products accused
Date: 30 September 2021Court: Federal Court of AustraliaJudge: Rofe J Background The patentee (Surefoot) alleged that...
Pearce IP BioBlast®: w/e 24 September 2021
18 Sep 21 | Merck announced that the first results from Ph III trials of Keytruda® (pembrolizumab) showed a...
Wrinkle for supplier of Botox ‘alternative’ as Court finds trade mark infringed, Australian Consumer Law breached
The Full Federal Court has held a supplier of cosmetic products (Self Care) liable to Allergan for infringing its...
Economy of court procedures primary factor in refusal to consider summary judgment application
Date: 22 September 2021Court: Federal Court of AustraliaJudge: Perram J Background Deco Australia Pty Ltd (Deco)...
New .au domain names coming to Australia
New .au domain names will be available in Australia from 24 March 2022. From this date, individuals, businesses and...
Pearce IP BioBlast®: w/e 17 September 2021
13 Sep 21 | Samsung Bioepis reported on a five-year follow-up study comparing ONTRUZANT® (trastuzumab biosimilar) with...